FindTrial
Sign In

CD19 CART

BIOLOGICAL6 trials

Sponsors

Shenzhen Second People's Hospital, Bioray Laboratories, Chinese PLA General Hospital, Beijing Boren Hospital

Conditions

Acute LeukemiaAutoimmune DiseaseB Cell LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Non-Hodgkin LymphomaRelapsed Acute Lymphoblastic LeukemiaRelapsed Non-Hodgkin Lymphoma

Phase 1

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
NCT03146533
Shenzhen Second People's HospitalB Cell Lymphoma
Start: 2017-05-31End: 2019-10-31Target: 20Updated: 2017-05-17
CD19-CART Treatment for ALL
CompletedNCT03232619
Bioray LaboratoriesAcute Leukemia
Start: 2018-08-01End: 2020-09-15Updated: 2020-09-22
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04012879
Chinese PLA General HospitalRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Start: 2019-05-01End: 2021-06-30Target: 12Updated: 2019-07-09
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma
NCT04012892
Chinese PLA General HospitalRefractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Start: 2019-05-01End: 2021-06-01Target: 12Updated: 2019-07-09

Unknown Phase

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
RecruitingNCT06983964
Beijing Boren HospitalAutoimmune Disease
Start: 2025-02-20End: 2027-09-30Target: 12Updated: 2025-05-21
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
RecruitingNCT06993493
Beijing Boren HospitalAutoimmune Disease
Start: 2025-02-20End: 2027-08-31Target: 12Updated: 2025-05-28

Related Papers

Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
BMJ Open2020-02-0149 citations